Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]

It is thought to reduce metastases. Early results show potential in renal cell cancers.[citation needed]

References

  1. ^ Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW (January 2010). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients". Cancer Chemotherapy and Pharmacology. 65 (2): 207–17. doi:10.1007/s00280-009-1023-8. PMID 19468731. S2CID 23035675.
Allikas: https://en.wikipedia.org/wiki/Volociximab
No tags for this post.